Cart
sales@molnova.com
BIRM 271
CAS No. 149106-77-4
BIRM 271( —— )
Catalog No. M37008 CAS No. 149106-77-4
BIRM 271 is a novel arachidonic acid release inhibitor that blocks leukotriene B4 and platelet-activating factor biosynthesis in human neutrophils.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 296 | Get Quote |
|
| 5MG | 409 | Get Quote |
|
| 10MG | 604 | Get Quote |
|
| 25MG | 908 | Get Quote |
|
| 50MG | 1251 | Get Quote |
|
| 100MG | 1647 | Get Quote |
|
| 500MG | 3312 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameBIRM 271
-
NoteResearch use only, not for human use.
-
Brief DescriptionBIRM 271 is a novel arachidonic acid release inhibitor that blocks leukotriene B4 and platelet-activating factor biosynthesis in human neutrophils.
-
DescriptionBIRM 271 is a novel arachidonic acid release inhibitor that blocks leukotriene B4 and platelet-activating factor biosynthesis in human neutrophils. BIRM 271 and BIRM 270 are enantiomers that inhibit the production of leukotriene B4 with IC50 of 40 nM.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMetabolic Enzyme/Protease
-
TargetPhospholipase
-
RecptorPhospholipase | LTR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number149106-77-4
-
Formula Weight335.44
-
Molecular FormulaC21H25N3O
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESN([C@H](CC1CCCCC1)C2=CC=CC=N2)C=3OC=4C(N3)=CC(C)=CC4
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
SB-435495
SB-435495 is a potent, orally active inhibitor of Lp-PLA2 with IC50 of 0.06 nM.
-
PHPS1
PHPS1 is an inhibitor of Shp2. PHPS1 efficiently inhibits activation of Erk1/2 by the leukemia-associated Shp2 mutant, Shp2-E76K, and blocks the anchorage-independent growth of a variety of human tumor cell lines.
-
Atg4B-IN-2
Atg4B-IN-2. A potent, selective Atg4B inhibitor with anticancer activity, inhibits both Atg4B and PLA2, enabling autophagy that counteracts the anticancer activity of anti-desiccation-resistant prostate cancer drugs.
